Egyptian deep technology healthcare startup DilenyTech, which is developing innovative artificial intelligence (AI) solutions for screening and diagnostic radiology workflow, has been acquired by US firm Astute Imaging LLC.
Founded in 2018, DilenyTech aims to revolutionise breast cancer screening and diagnostic workflow by providing innovative AI-based assistance for more accurate detection and expedited reporting.
The startup develops solutions for medical imaging analysis, breast cancer risk assessment, and structured reporting in several medical applications, and has provided its services to top-tier international health-tech companies with active users in three different continents.
Having secured US$160,000 in grant funding last year, DilenyTech has now been acquired by Astute Imaging, a provider of imaging guided therapy and procedure planning services. The acquisition will enable Astute Imaging to leverage the power of AI to improve its current offering, expand services and develop innovative solutions in the medical imaging domain.
“This strategic acquisition of DilenyTech will enable Astute Imaging to expedite the development of an AI driven image-guided therapy platform and add more automation to our imaging services and procedure planning solutions,” said Wael Elseaidy, co-founder and CEO of Astute Imaging. “Empowering our surgery planning and patient follow-up imaging platforms with AI will help our customers and medical imaging stakeholders to provide more patient centric proactive services.”
“We are excited to be part of Astute Imaging’s amazing team and adopt our expertise and technologies to build reliable AI technologies for imaging-guided therapy,” said Ahmed Ehab Mahmoud, DilenyTech founder and innovation director, who will be joining Astute Imaging’s founding team and managing the imaging operations.
“We have applied our technologies successfully in the area of breast imaging and we look forward to expanding our AI pipeline to other imaging areas such as thyroid, liver and gynecology as well as cardiovascular 3D imaging and procedural planning. We believe Astute Imaging will be a gamechanger for healthcare providers and device companies.”